近日，食品安全标准与监测评估司发布了《关于栀子油等22种"三新食品"的公告》，其中多项原料涉及合成生物学方法，也有部分企业已经率先布局。 其中有市场规模近十亿的热门原料，也有应用版图稳步扩张的前沿新品，尤其是多家HMOs相关产品大量获批，智药局对相关原料及企业进行了梳理，与 您一同洞察市场先机。 伊利 X 澳优联手 "中国菌"崛起 首先是益生菌产品长双歧杆菌婴儿亚种YLGB-1496获批新食品原料。 | | | | 中文名称 | 长双歧杆菌婴儿亚种 YLGB-1496 | | --- | --- | | 拉丁名称 | Bifidobacterium longum subsp. infantis | | | YLGB-1496 | | | 其他需要说 1. 批准列入《可用于婴幼儿食品的菌种名单》。 | | 明的情况 | 2. 食品安全指标应符合《食品安全国家标准 | | | 食品加工用菌种制剂》(GB 31639)，同时 | | | 克罗诺杆菌属不得检出(/100g) | 本产品从母乳中分离获得，可用于婴幼儿食品的菌种用于食品中直接食用，同时已被列入我国《可用于食品的菌种名单》和欧洲食品安全局资格认定 （QPS ...

Core Insights - The approval of Bifidobacterium longum subsp. infantis YLGB-1496 for inclusion in the list of probiotics for infant food marks a significant advancement in ensuring the health of infants in China, showcasing the technical strength of the company involved, Ausnutria [1][2][3] Group 1: Product Approval and Significance - The strain YLGB-1496 has been officially recognized for its safety and efficacy, meeting stringent national standards for probiotics used in infant food [2][3] - This approval positions the company as a leader in the infant probiotic market, having two nationally recognized strains, reinforcing its commitment to high-quality infant nutrition [1][5] Group 2: Research and Clinical Evidence - YLGB-1496 has demonstrated significant clinical benefits, including a reduction in the incidence of eczema in infants and improvements in immune function, as evidenced by increased levels of immunoglobulins [3][5] - The strain has also shown positive effects on weight gain and digestive health in children aged 1-3 years, indicating its role in enhancing nutrient absorption and overall health [3][5] Group 3: Industry Collaboration and Market Impact - The collaboration between Ausnutria and Yili Group has been pivotal in the successful commercialization of YLGB-1496, with a well-established model for production and marketing of probiotics [6][9] - The strain has been integrated into various products within Yili's portfolio, demonstrating its versatility and potential for broad application across different food categories [8][9] Group 4: Future Prospects and Strategic Goals - The company aims to continue exploring the functional mechanisms of YLGB-1496 and expand its applications in diverse food forms, maintaining a focus on high standards for infant probiotics [9] - Ongoing collaboration with industry partners is expected to drive innovation and enhance the competitiveness of the Chinese probiotic industry, contributing to public health, particularly for infants [9]